IGF-1 supplements: what a surgeon's TikTok likely gets right and wrong

What's this video probably claiming?

Based on the caption and hashtag context, Dr. Richman is likely walking viewers through the basic physiology of insulin-like growth factor 1 (IGF-1), its relationship to human growth hormone (HGH), and then pivoting to a warning about IGF-1 supplements or secretagogues. The cancer awareness hashtag is a giveaway. He almost certainly invokes the IGF-1/cancer hypothesis, suggesting that elevated IGF-1 promotes tumor growth, and uses that as the core reason to avoid supplementation. Given his cardiothoracic background, he may also touch on cardiovascular risks associated with supraphysiological IGF-1 levels. The category context here matters too: the video sits adjacent to conversations about peptides like MK-677 and CJC-1295 that indirectly raise IGF-1 by stimulating growth hormone release. His advice to avoid IGF-1 supplements may or may not account for that distinction between exogenous IGF-1 and GH secretagogues.

What does the science actually show?

The IGF-1 and cancer relationship is real but messy. A large prospective analysis by Giovannucci et al. (2000, Science) found that men in the highest quartile of circulating IGF-1 had roughly 4 times the risk of prostate cancer compared to those in the lowest quartile. The Hankinson et al. (1998, Lancet) cohort found similar associations in premenopausal breast cancer. But these are observational data. They show correlation, not causation, and critically, they reflect endogenous IGF-1 levels, not supplementation outcomes. Recombinant IGF-1 (mecasermin) does exist as an FDA-approved drug for severe primary IGF-1 deficiency in children, dosed at 0.04 to 0.12 mg/kg twice daily under strict monitoring. The cancer risk at those therapeutic doses remains under study. Most commercial IGF-1 supplements are derived from deer antler velvet and contain negligible bioavailable IGF-1, which adds another layer of skepticism that a surgeon advising against them may not fully address.

Where does the social media noise diverge from clinical reality?

The noise runs in two directions simultaneously, which is what makes this topic frustrating to fact-check. On one side, you have biohackers treating IGF-1 elevation as an unambiguous performance win, stacking MK-677 at 25 mg/day with peptides like CJC-1295 to drive IGF-1 into the upper ranges without any clinical supervision or baseline labs. On the other side, you get blanket warnings from physicians that treat any IGF-1 elevation as equivalent to fueling cancer, which overstates the current evidence. The reality sits between those poles. Laron syndrome patients with near-zero IGF-1 due to GH receptor defects show almost zero incidence of cancer (Guevara-Aguirre et al., 2011, Science Translational Medicine), which is genuinely striking. But extrapolating that to mean suppressing IGF-1 in healthy adults is protective, or that modestly elevating it via a peptide protocol is dangerous, is a leap the data does not yet support. Clinical context, baseline levels, and individual risk factors matter enormously.

What should you actually know?

If you're watching this video and considering any protocol that influences IGF-1, including GH secretagogues like ipamorelin or MK-677, a few things are worth knowing. First, most over-the-counter IGF-1 supplements almost certainly don't deliver meaningful systemic IGF-1. Oral bioavailability is essentially nil for intact IGF-1 peptides. Second, the long-term safety data for GH secretagogues in healthy adults is thin. MK-677 has been studied in older adults at 25 mg/day over 12 months (Nass et al., 2008, Annals of Internal Medicine) with some lean mass benefits but also significant increases in fasting glucose and insulin resistance. Third, anyone with a personal or family history of hormone-sensitive cancers should have a genuinely serious conversation with an oncologist before pursuing any protocol that raises IGF-1 above physiological range. A cardiothoracic surgeon advising against IGF-1 supplements is not wrong in principle, but the nuance matters, and blanket avoidance messaging without mechanistic context leaves viewers less equipped to ask the right questions.